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Introduction and Background
Inflammatory diseases such as cancer and congestive heart
failure (CHF) may be accompanied by cachexia, a progressive
wasting of muscle mass (atrophy). The proinflammatory
cytokine TNF α is known to play a role in causing cachexia.
Cytokines act as signaling molecules that communicate between
cells. TNF α can stimulate neutral sphingomyelinase-3
(nSMase-3), an enzyme that hydrolyzes phospholipids in the
cell membrane to produce ceramide, a lipid-signaling molecule. TNF α is also known to activate
the protein complex NF-kB, which controls the transcription of DNA. Abnormal regulation of
NF-kB has been associated with cancer and other inflammatory diseases. Our data show that
inhibition of nSMase-3 activity is linked to a decrease in p38 MAPK activity. NF-kB and p38
MAPK are signaling molecules that promote protein breakdown.
It has been established that TNF α causes muscle atrophy and stimulates nSMase-3. However,
we do not know very much about the role of nSMase/ceramide signaling in the atrophy response.
Would inhibiting nSMase-3 activity preserve muscle mass? Our data show that nSMase-3
promotes loss of muscle proteins, actin and myosin, suggesting that nSMase-3 is a key regulator
in muscle wasting. Based on these findings, we hypothesized that increasing activity of nSMase3 causes skeletal muscle wasting as evidenced by a decrease in myotube width and degradation
of muscle proteins actin and myosin.
Experimental Methodology and Results
A cell culture model of cachexia was used. Cell cultures of C2C12 myotubes were divided into
four treatment groups as follows: 1.) wildtype control, 2.) nSMase-3 deficient control, 3.)
wildtype + TNF α, and 4.) nSMase-3 deficient + TNF α. Experimental myotubes were treated
with TNF α once every 24 hours for three days. The wildtype control did not undergo any
experimental intervention. The nSMase-3 deficient control had inhibited activity of nSMase-3.
Inhibiting expression of nSMase-3
Small interfering RNA (siRNA) is a category of double stranded RNA molecules that can be
used to inhibit gene expression. For the purposes of this study, siRNA that is nSMase-3 specific
was used to inhibit gene expression, resulting in mRNA degradation. As a result, mRNA
expression should decrease. Changes in mRNA expression were measured using real time PCR.
Results indicated that mRNA expression had markedly decreased indicating that the knockdown
of nSMase-3 was successful.
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Measuring nSMase-3 total protein content
The nSMase-3 total protein content was also measured using Western blotting. Our results
indicated that nSMase-3 total protein was lower in nSMase-3 knockdown myotubes compared to
those myotubes that were not nSMase-3 deficient (i.e. wildtype control, wildtype + TNF α).
Measuring actin and myosin protein content
Major muscle proteins actin and myosin were measured to determine the degree of muscle
wasting in each of the treatment groups. Cultured C2C12 myotubes were transfected with
nSMase-3 specific siRNA to knockdown gene expression. We used Western blot to measure
protein content. Myosin and total protein were elevated compared to the treatment groups that
were not nSMase-3 deficient (i.e. wildtype control, wildtype + TNF α). Myotubes were also
transfected with pAcGFP fusion plasmid to induce overexpression of nSMase-3. Total protein
and myosin proteins were decreased.
Measuring myotube width
Measuring myotube width also serves as a direct method of investigating the extent of muscle
atrophy. Myotube images were taken under a specialized microscope from each treatment group.
From these images, myotube width was directly measured using image analysis software such as
Image J. Myotube width is directly proportional to myosin and actin content. Cultured C2C12
myotubes were pretreated with nSMase-3 siRNA or nonsense siRNA then treated with vehicle
(control) or TNF α. Myotubes pretreated with nSMase-3 siRNA and then TNF α showed an
increase in myotube width compared to the control. On the other hand, myotubes pretreated with
nonsense siRNA and then TNF α showed a decrease in myotube width with respect to the
control.
Conclusions
The outcome of the research seems to be very promising. As expected, inhibiting expression of
nSMase-3 showed an increase in myosin and total protein and overexpression of nSMase-3
resulted in a decrease in protein content. These findings further suggest that nSMase-3 may be a
key regulator in muscle wasting. More experiments are being conducted to investigate catabolic
signaling pathways associated with nSMase-3. For example, we are now measuring IkB total
protein as well as p38 MAPK phosphorylation, both markers of catabolic signaling.

